Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,022.40 +0.19 (+0.00%) Dow
37,874.84 +121.53 (+0.32%) Nasdaq
15,654.75 -28.62 (-0.18%) Bitcoin USD
62,409.18 -371.65 (-0.59%) CMC Crypto 200
885.54 0.00 (0.00%)
MacroGenics, Inc. (MGNX)
| Previous close | 16.10 |
| Open | 15.99 |
| Bid | 15.79 x 600 |
| Ask | 16.00 x 600 |
| Day's range | 15.82 - 16.10 |
| 52-week range | 4.29 - 21.88 |
| Volume | |
| Avg. volume | 1,595,653 |
| Market cap | 993.461M |
| Beta (5Y monthly) | 2.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.15 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.78 |
GlobeNewswireMacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing
Insider MonkeyMacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript March 7, 2024 MacroGenics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. We will begin the MacroGenics 2023 Fourth Quarter Corporate Progress and Financial Results Conference Call in just […]
Insider Monkey12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]
